Actively Recruiting
First-in-Human Phase 1 Study of SIM0610 Given by Intravenous Infusion to Adults with Advanced or Metastatic Solid Tumors
Led by Jiangsu Simcere Pharmaceutical Co., Ltd. · Updated on 2026-01-23
260
Participants Needed
7
Research Sites
82 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating SIM0610 in a first-in-human, open-label, multicenter study to assess its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in adults with locally advanced or metastatic solid tumors. The study uses accelerated titration and Bayesian optimal interval design methods to guide dose escalation, aiming to understand how SIM0610 behaves in the body and its potential effect on various advanced solid cancers. Participants will receive SIM0610 through intravenous infusion in two parts of the study part 1 focuses on dose escalation to find appropriate dose levels, and part 2 expands the cohort to further assess anti-tumor effects at the recommended dose. Treatment is given according to the study protocol, with doses and schedules carefully monitored throughout. During the study, participants will be closely monitored for dose-limiting toxicities within about 21 days after the first dose and safety up to 28 days following the last dose. Tumor response will be evaluated for up to approximately two years to assess the objective response rate. Participants will undergo assessments including tumor lesion evaluations using RECIST criteria, organ function tests, and provide tumor tissue samples before treatment. The study aims to collect detailed data on safety and possible anti-tumor activity over the course of treatment and follow-up.
CONDITIONS
Brief Title
First in Human Study of SIM0610 in Solid Tumors
Research Team
J
Jiawei Yao
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here